Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Inmagene Biopharmaceuticals

Request full access

Inmagene is a clinical-stage biotech company developing innovative and differentiated therapies for immunological and inflammatory diseases

San Diego, United StatesFounded 2019Biotech & Life Sciences

About Inmagene Biopharmaceuticals

Inmagene Biopharmaceuticals is a biopharmaceutical company dedicated to developing innovative treatments for autoimmune diseases. The company operates in the global healthcare market, targeting a range of autoimmune conditions that affect millions of patients worldwide. Inmagene's business model revolves around research and development (R&D) of new drugs, with a focus on cost-efficient innovation to bring effective therapies to market. The company generates revenue through the commercialization of its proprietary drugs, as well as through partnerships and licensing agreements with other pharmaceutical companies. Inmagene serves a diverse client base, including healthcare providers, hospitals, and patients in need of advanced treatment options for autoimmune diseases. The company has secured significant funding, including a $21 million Series B financing round, to support its R&D efforts and expand its market presence. Inmagene's strategic locations in Hangzhou, Shanghai, and San Diego enable it to leverage global expertise and resources in the biopharmaceutical industry.

Source: Dealroom company data

At a glance

Status
Operational
Employees
47
Open positions
1
Dealroom signal
82.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Dec 2024
Capital deployed
—
Preferred round
ACQUISITION

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
PRIVATE PLACEMENT VCOther financing Apr 2026 $30M — OrbiMed · Coastlands Capital · OmegaFunds · Trails Edge Capital Partners ↗
IPOOther financing Dec 2024 $0 — Undisclosed ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Inmagene Biopharmaceuticals website traffic

Latest recorded traffic for Inmagene Biopharmaceuticals is 2.8K monthly website visits, down 68.2% over the last three months. Inmagene Biopharmaceuticals's team declined 6% over the past year.

Latest monthly visits2.8K 3-month web change-68.2% 1-year team growth-6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Inmagene Biopharmaceuticals in the San Diego ecosystem

Live from Dealroom

The Inmagene Biopharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Vertex Ventures China
  • South China Venture Capital
  • Kunlun Capital
  • Panacea Venture

Series B and later5 investors entered at this stage

  • Highlight Capital
  • Kunlun Fund
  • TMT Investments
  • TriWise Capital
  • VMS Group

Other known investors4 additional known investors

  • Coastlands Capital
  • OmegaFunds
  • OrbiMed
  • Trails Edge Capital Partners
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China62.5%
🇺🇸 United States37.5%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Inmagene Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Inmagene Biopharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.